Amgen Inc. announced Thursday that the U.S. Food and Drug Administration accepted a biologics license application and granted priority review for Tezepelumab, an asthma drug developed in collaboration with AstraZeneca. ...

Join our Membership to get the full story.


Are you a current Member? Sign In